文献速递神经PET

PET示踪剂鉴别胶质瘤肿瘤复发与治疗相关变化的诊断价值:系统综述与Meta分析

Diagnostic Value of PET Tracers in Differentiating Glioma Tumor Recurrence from Treatment-Related Changes: A Systematic Review and Meta-Analysis.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-04-02

该系统综述与Meta分析纳入28项研究、1405例胶质瘤患者,比较10种PET示踪剂鉴别肿瘤进展与治疗相关变化的诊断准确性。11C-MET诊断价值最高,汇总敏感度0.89、特异度0.91;18F-FDOPA研究数量有限但敏感度1.00、特异度0.92。作者认为氨基酸类示踪剂诊断价值最高。

要点

  • 11C-MET鉴别胶质瘤肿瘤进展与治疗相关变化的汇总敏感度0.89、特异度0.91,诊断价值最高。
  • 18F-FDOPA研究数量有限,汇总敏感度1.00、特异度0.92,诊断价值高。
  • 作者认为氨基酸类示踪剂诊断价值最高,11C-MET与18F-FDOPA优势最明显。

核心结论

  • 氨基酸类示踪剂在鉴别胶质瘤治疗相关变化与肿瘤进展方面诊断价值最高,其中11C-MET与18F-FDOPA优势最明显。
  • 其他新示踪剂的研究有限,因此需要进一步研究以证明其诊断价值。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Web of Science和EMBASE数据库,按设定标准纳入28项使用PET鉴别胶质瘤肿瘤进展与治疗相关变化的研究。
  • 共涉及10种不同示踪剂和1405例患者,其中肿瘤进展占67.4%(947例),治疗相关变化占32.6%(458例)。

诊断标准与关键数值

  • 纳入比较的10种示踪剂包括18F-FDG、11C-MET、18F-FET、18F-FDOPA、18F-FLT、18F-PSMA-1007、68Ga-PSMA-11、18F-CHO、18F-fluciclovine和11C-AMT。

临床应用与阅片要点

  • 作者认为氨基酸类示踪剂在鉴别胶质瘤治疗相关变化与肿瘤进展时诊断价值最高,11C-MET与18F-FDOPA优势最明显。
  • 作者指出其他新示踪剂的研究有限,需要进一步研究证明其诊断价值。

局限性

  • 多数研究样本量小。
  • 纳入研究在最终诊断的参考标准与诊疗标准方面存在一定程度差异。
  • 多数入选研究为回顾性研究。
  • 其他新示踪剂的研究有限,需要进一步研究证明其诊断价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: It is often difficult to identify treatment-related changes (TRC) from tumor progression (TP) in patients with glioma, and the current application of PET scanning is expected to improve the diagnosis.

PURPOSE: We used a systematic review and meta-analysis to reveal diagnostically more promising tracers by comparing the diagnostic accuracy of different PET tracers in identifying TRC and TP in patients with glioma.

DATA SOURCES: We searched PubMed, Web of Science, and EMBASE databases, and we selected studies that used PET scans to identify TP and TRC in patients with glioma.

STUDY SELECTION: Twenty-eight studies were identified based on the set criteria. The studies involved a total of 10 different tracers and 1405 patients. TP occurred in 67.4% (947) of patients, while TRC occurred in 32.6% (458) of patients.

DATA ANALYSIS: The sensitivity, specificity, diagnostic odds ratio, positive likelihood ratio, and negative likelihood ratio of various PET tracers were calculated and summarized. Moreover, the diagnostic value of various tracers was compared.

DATA SYNTHESIS: This systematic review included 28 studies comparing 10 different PET tracers, including 18F-fluoro-deoxy-glucose FDG (18F-FDG), 11C methionine (11C -MET), 18F-fuoroethyl-L-tyrosine (18F-FET), 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine (18F-FDOPA), 18F-fluorothymidine (18F-FLT), 18F-PSMA-1007, 68Ga-PSMA-11, 18F-choline (18F-CHO), 18F-fluciclovine, and [11]C-Alpha-Methyl-Tryptophan(11C-AMT). The results revealed that 11C-MET exhibited the highest diagnostic value, with an overall sensitivity and specificity of 0.89 [0.85, 0.93] and 0.91 [0.84, 0.99], respectively. Although the number of 18F-FDOPA studies is limited, it exhibited high diagnostic value, with an overall sensitivity and specificity of 1.00 [0.91, 1.00] and 0.92 [0.75, 0.99], respectively.

LIMITATIONS: Most studies consisted of small sample sizes; however, the included studies differed to some extent regarding the reference standard for the final diagnosis and the standard of care. Additionally, most selected studies were retrospective.

CONCLUSIONS: Amino acid-based tracers exhibited the highest diagnostic value in identifying TRC and TP in gliomas, with 11C-MET and 18F-FDOPA having the most notable advantages. Research on other new tracers is limited, therefore, further studies are needed to prove their diagnostic value.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Kou Y, Zhou W, et al. Diagnostic Value of PET Tracers in Differentiating Glioma Tumor Recurrence from Treatment-Related Changes: A Systematic Review and Meta-Analysis. AJNR Am J Neuroradiol. 2025. PMID: 40174979. doi:10.3174/ajnr.A8565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。